Immune checkpoint inhibitors (ICIs) are approved for the treatment of a variety of cancer
types. The doses of these drugs, though approved by the Food and Drug Administration …

Immune checkpoint inhibitors have revolutionised cancer treatment by offering durable
responses to many patients with solid and haematological cancers. The high prices and …

Abstract Chitinase-3-like protein 1 (CHI3L1) is a secreted glycoprotein that mediates
inflammation, macrophage polarization, apoptosis, and carcinogenesis. The expression of …

Immunotherapy has emerged to play a rapidly expanding role in the treatment of cancers.
Currently, many clinical trials of therapeutic agents are on ongoing with majority of immune …

Immune checkpoint inhibitors (ICIs) are a revolutionary breakthrough in the field of cancer by
modulating patient's own immune system to exert anti-tumor effects. The clinical application …

Increasing evidence suggests that some immunotherapy dosing regimens for patients with
advanced cancer could result in overtreatment. Given the high costs of these agents, and …

Nivolumab and pembrolizumab, anti–programmed cell death protein 1 monoclonal
antibodies, have revolutionized oncology but are expensive. Using an interventional …

Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the
management of multiple malignancies including lung cancer. However, the optimal use of …

Immune checkpoint inhibitor therapy has become a promising option for the treatment of late-
stage thymic epithelial tumors. In this manuscript, we presented a patient with metastatic …

Surface plasmon resonance (SPR) phenomena have been widely studied to detect
biomolecules because of their high sensitivity and ability to determine biomolecular …